23andMe Investor Presentation Deck

'610 Next Steps • Complete enrollment of Phase 2a Dose Expansion Cohorts Recently expanded Neuroendocrine, Ovarian cohorts o Initial Phase 2a data cohorts planned to be presented mid-2024 O o Clinical development planning for Fast-to-Market strategies o Potential clinical combinations with assets with complementary mechanisms, to support earlier line indications Seeking partnerships to expand Phase 2a and conduct randomized Phase 2b/3 clinical trials - multiple readouts expected in 2024 Copyright © 2024 23and Me, Inc. 23andMe 30

View entire presentation